Clinical trials: Resistant to Conventional Therapy
Graft vs Host Disease
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
The objectives of this study are to determine the efficacy and safety of BEGEDINA® in subjects with steroid resistant acute graft versus host disease (GvHD).
- Trial name
- NCT02411084
- Testing
- Begelomab, Conventional Second-line Treatment
- Where
- 27 sites in United States, France and 5 more
- Volunteers
- 36 people
- Sponsor
- Adienne SA